Influence of drugs with hyaluronidase activity on the survival of animals with a purulent-inflammatory process in the abdominal organs

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: The optimization of the pharmacokinetics of antibiotics is an important aspect in improving the effectiveness of therapy for intra-abdominal infections. Thus, studying the survival of experimental animals with a simulated purulent-inflammatory process in abdominal organs using the combined use of antibacterial agents with endolymphatic agents is worthwhile.

AIMS: To examine the effect of the co-administration of cefotaxime and hyaluronidase or bovgyaluronidase azoximer on the survival of mice with a purulent-inflammatory process of the abdominal organs.

MATERIALS AND METHODS: The purulent-inflammatory process of the abdominal organs, which was simulated by the intraperitoneal administration of a lethal dose of Staphylococcus aureus microbial suspension to mice, was evaluated. Four study groups were formed, with 28 animals each. Group 1 did not receive treatment, group 2 was administered with cefotaxime, and groups 3 and 4 received antibiotics after preliminary administration of hyaluronidase or bovgialuronidase azoximer. For the statistical analysis of animal survival, the Kaplan–Meier multiple assessment method was used, and a univariate analysis using a log-rank test was employed to identify significant differences between the groups.

RESULTS: During the study, a single injection of cefotaxime alone and in combination with other studied drugs promoted the survival of some mice with a simulated purulent-inflammatory process of the abdominal organs compared with the untreated group, and at the end of the experiment (day 7), 100% of the animals died. Moreover, the best results were achieved with the initial administration of hyaluronidase or bovhyaluronidase azoximer. Thus, on day 7 of observation, >70% of the animals in groups that received both an antibiotic and hyaluronidase or bovgyaluronidase azoximer survived. No statistically significant differences were found in the effect of these drugs on animal survival in the presence of an experimental purulent-inflammatory process.

CONCLUSION: A single injection of cefotaxime alone or in combination with other studied drugs ensures the survival of some mice with a simulated purulent-inflammatory process of the abdominal cavity compared with the control group, in which 100% of the animals died by the end of the experiment (day 7). Moreover, the best results were achieved in groups initially administered with hyaluronidase or bovgialuronidase azoximer.

About the authors

German V. Kukushkin

Pirogov Russian National Research Medical University

Email: germanpharm@yandex.ru
ORCID iD: 0000-0002-1661-1071

MD, Cand. Sci. (Med.), associate professor

Russian Federation, 1 Ostrovityanova street, 117997 Moscow

Marina V. Zhuravleva

I.M. Sechenov First Moscow State Medical University (Sechenov University); Scientific Centre for Expert Evaluation of Medicinal Products

Email: clinpharm23@mail.ru
ORCID iD: 0000-0002-9198-8661
SPIN-code: 6267-9901

MD, Dr. Sci. (Med.), professor

Russian Federation, 1 Ostrovityanova street, 117997 Moscow; Moscow

Dmitry E. Yurov

Pirogov Russian National Research Medical University

Author for correspondence.
Email: dmpharm@gmail.com
ORCID iD: 0000-0003-0178-8736
SPIN-code: 6403-4087

MD, Cand. Sci. (Med.)

Russian Federation, 1 Ostrovityanova street, 117997 Moscow

References

  1. Sartelli M, Coccolini F, Kluger Y, et al. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. World J Emerg Surg. 2021;16(1):49. doi: 10.1186/s13017-021-00387-8
  2. Morvan AC, Hengy B, Garrouste-Orgeas M, et al. Impact of species and antibiotic therapy of enterococcal peritonitis on 30-day mortality in critical care-an analysis of the OUTCOMEREA database. Crit Care. 2019;23(1):307. doi: 10.1186/s13054-019-2581-8
  3. Luo X, Li L, Xuan J, et al. Risk factors for enterococcal intra-abdominal infections and outcomes in intensive care unit patients. Surg Infect (Larchmt). 2021;22(8):845–853. doi: 10.1089/sur.2020.417
  4. Bassetti M, Rello J, Blasi F, et al. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. Int J Antimicrob Agents. 2020;56(6):106184. doi: 10.1016/j.ijantimicag.2020.106184
  5. De Waele JJ, Schouten J, Beovic B, et al. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions — a viewpoint of experts. Intensive Care Med. 2020;46(2):236–244. doi.org/10.1007/s00134-019-05871-z
  6. Gatti M, Viaggi B, Rossolini GM, et al. An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of BSIs, cUTIs, and cIAIs caused by enterobacterales in critically ill adult patients. Infect Drug Resist. 2021;14:2461–2498. doi: 10.2147/IDR.S314241
  7. Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy. 2014;6(5):553–567. doi: 10.2217/imt.14.34
  8. Locke KW, Maneval DC, LaBarre MJ. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019;26(1): 98–106. doi: 10.1080/10717544.2018.1551442
  9. Orehova JeM, Konchugova TV, Luk’janova TV, i dr. Primenenie preparata «Longidaza 3000 ME» pri zabolevanijah, soprovozhdajushhihsja patologiej soedinitel’noj tkani. Moscow; 2008. (In Russ).
  10. Konenkov VI, Borodin JuI, Ljubarskij MS. Limfologija. Novosibirsk: Izdatel’skij dom «Manuskript»; 2012. (In Russ).
  11. Levin JuM, Rodionova OM, Gurina LV, i dr. Patogeneticheskaja terapija (ustranenie anahronizmov). Novye principy i metody. Moscow: Izdatel’stvo RUDN; 2014. (In Russ).
  12. Vtorenko VI, Esipov AV, Musailov VA, Shishlo VK. Limfaticheskaja terapija v hirurgicheskoj praktike. SurgicaL Practice. 2014;(3):4–9. (In Russ).
  13. Charyshkin AL, Dementyev IN. Results regionarny limfotropny of therapy of patients sharp paraproktitis. Ul’yanovskii mediko-biologicheskii zhurnal. 2013;(3)45–53. (In Russ).
  14. Usubakunov UE. Effectiveness of lymph-stimulating therapy in syndrome systemic inflammatory reaction in abdominal surgery. Vestnik of KSMA named after I.K. Akhunbayev. 2015;2(2):155–158. (In Russ).
  15. Kraynyukov PE, Safonov OV, Kolodkin BB, Kokorin VV. Pyoinflammatory diseases brush: modern features of complex treatment. Bulletin of Pirogov National Medical & Surgical Center. 2016;11(3):48–54. (In Russ).
  16. Oschepkova OV, Putalova IN, Barinov SV, Sabitov SS. The way of treatment of complicated forms of inflammatory diseases of appendages of uterus by application lymphotropic introductions of antibacterial medicine. Omsk Scientific Bulletin. 2012;(1):114–119. (In Russ).
  17. Skripcova SA, Tverdohleb SA. Ocenka rezul’tatov lechenija skleroza shejki mochevogo puzyrja. Saratov Journal of Medical Scientific Research. 2016;12(2):232. (In Russ).
  18. Sviridkina LP, Batysheva TT, Kuzmina ZV, Toporova SG. Lymphotropic therapy of dorsopathy in case of disc hernia if the lumbar part of the spinal column. Vestnik Rossiiskogo gosudarstvennogo meditsinskogo universiteta. 2011;(1):36–40. (In Russ).
  19. Borisov IM, Shapovalova TG, Krainyukov PE. Indirect lymphotropic therapy at pneumonia. Yakut Medical Journal. 2011;(3):34–36. (In Russ).
  20. Krotov SY, Krotov YA, Putalova IN. Regional lymphotropic therapy for acute otitis media using low-frequency ultrasound. Russian Otorhinolaryngology. 2013;64(3):89–93. (In Russ).
  21. Bratko VI, Smagin AA, Khabarov DV, Demura AY. Use of lymphotropic technologies for the correction of the inflammatory process in diabetic retinopathy. Mezhdunarodnyi zhurnal ehksperimental’nogo obrazovaniya. 2013;(10-2):246–249. (In Russ).
  22. Volchegorskij IA, Dolgushin II, Kolesnikov OL, i dr. Jeksperimental’noe modelirovanie i laboratornaja ocenka adaptivnyh reakcij organizma. Cheljabinsk: Izd-vo Cheljabinskogo gosudarstvennogo pedagogicheskogo universiteta; 2000. 167 p. (In Russ).
  23. Thomas JR, Wallace MS, Yocum RC, et al. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage. 2009; 38(5):663–678. doi.org/10.1016/j.jpainsymman.2009.03.009
  24. https://grls.rosminzdrav.ru/ [Internet]. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata LongidazA® (Longidaza®) [cited: Feb 01, 2023]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=24753d71-5447-43ae-a8b7-46ae45216a0a (In Russ).
  25. Kukushkin GV, Zhuravleva MV, Sviridkina LP, Yurov DE. Hyaluronidase: an experimental confirmation of the properties of the endolymphatic conductor. Rossiiskii meditsinskii zhurnal (Medical Journal of the Russian Federation, Russian Journal). 2019;25(1): 40–43. (In Russ). doi: 10.18821/0869-2106-2019-25-1-40-43
  26. Zhuravleva MV, Kukushkin GV, Sviridkina LP, et al. Experimental study of the pharmacokinetics of cefotaxime with joint administration of drugs with hyaluronidase activity. Antibiotics and Chemotherapy. 2019;64(5-6):9–12. (In Russ). doi: 10.24411/0235-2990-2019-10024

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Survival of mice in groups of animals with simulated abdominal purulent inflammation without treatment and those injected with cefotaxime (CF) alone.

Download (294KB)
Indexing metadata
3. Fig. 2. Survival of mice in groups of animals with simulated abdominal purulent inflammation injected with cefotaxime (CF) alone and combined administration with hyaluronidase (HLRD).

Download (291KB)
Indexing metadata
4. Fig. 3. Survival of mice in groups of animals with simulated abdominal purulent inflammation injected with cefotaxime alone (CF) and combined administration with bovhyaluronidase azoximer (BHLRD+Az).

Download (289KB)
Indexing metadata

Copyright (c) 2023 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies